Literature DB >> 32960673

A preoperative radiomics model for the identification of lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.

Lifen Yan1,2, Huasheng Yao2,3, Ruichun Long4, Lei Wu2,3, Haotian Xia2,3, Jinglei Li2, Zaiyi Liu1,2, Changhong Liang1,2.   

Abstract

OBJECTIVES: To develop and validate a radiomics model for preoperative identification of lymph node metastasis (LNM) in patients with early-stage cervical squamous cell carcinoma (CSCC).
METHODS: Total of 190 eligible patients were randomly divided into training (n = 100) and validation (n = 90) cohorts. Handcrafted features and deep-learning features were extracted from T2W fat suppression images. The minimum redundancy maximum relevance algorithm and LASSO regression with 10-fold cross-validation were used for key features selection. A radiomics model that incorporated the handcrafted-signature, deep-signature, and squamous cell carcinoma antigen (SCC-Ag) levels was developed by logistic regression. The model performance was assessed and validated with respect to its calibration, discrimination, and clinical usefulness.
RESULTS: Three handcrafted features and three deep-learning features were selected and used to build handcrafted- and deep-signature. The model, which incorporated the handcrafted-signature, deep-signature, and SCC-Ag, showed satisfactory calibration and discrimination in the training cohort (AUC: 0.852, 95% CI: 0.761-0.943) and the validation cohort (AUC: 0.815, 95% CI: 0.711-0.919). Decision curve analysis indicated the clinical usefulness of the radiomics model. The radiomics model yielded greater AUCs than either the radiomics signature (AUC = 0.806 and 0.779, respectively) or the SCC-Ag (AUC = 0.735 and 0.688, respectively) alone in both the training and validation cohorts.
CONCLUSION: The presented radiomics model can be used for preoperative identification of LNM in patients with early-stage CSCC. Its performance outperforms that of SCC-Ag level analysis alone. ADVANCES IN KNOWLEDGE: A radiomics model incorporated radiomics signature and SCC-Ag levels demonstrated good performance in identifying LNM in patients with early-stage CSCC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32960673      PMCID: PMC7715994          DOI: 10.1259/bjr.20200358

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  33 in total

1.  Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis.

Authors:  Hyuck Jae Choi; Woong Ju; Seung Kwon Myung; Yeol Kim
Journal:  Cancer Sci       Date:  2010-02-11       Impact factor: 6.716

2.  Value of Dynamic Contrast-enhanced and Diffusion-weighted MR Imaging in the Detection of Pathologic Complete Response in Cervical Cancer after Neoadjuvant Therapy: A Retrospective Observational Study.

Authors:  Aurélie Jalaguier-Coudray; Rim Villard-Mahjoub; Aurélie Delouche; Béatrice Delarbre; Eric Lambaudie; Gilles Houvenaeghel; Mathieu Minsat; Agnès Tallet; Renaud Sabatier; Isabelle Thomassin-Naggara
Journal:  Radiology       Date:  2017-03-16       Impact factor: 11.105

3.  A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.

Authors:  Shaoxu Wu; Junjiong Zheng; Yong Li; Hao Yu; Siya Shi; Weibin Xie; Hao Liu; Yangfan Su; Jian Huang; Tianxin Lin
Journal:  Clin Cancer Res       Date:  2017-09-05       Impact factor: 12.531

4.  Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.

Authors:  F Landoni; A Maneo; A Colombo; F Placa; R Milani; P Perego; G Favini; L Ferri; C Mangioni
Journal:  Lancet       Date:  1997-08-23       Impact factor: 79.321

Review 5.  The revised FIGO staging system for uterine malignancies: implications for MR imaging.

Authors:  Susan J Freeman; Ahmed M Aly; Masako Y Kataoka; Helen C Addley; Caroline Reinhold; Evis Sala
Journal:  Radiographics       Date:  2012-10       Impact factor: 5.333

Review 6.  The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.

Authors:  Angiolo Gadducci; Roberta Tana; Stefania Cosio; Andrea Riccardo Genazzani
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-26       Impact factor: 6.312

7.  Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.

Authors:  J M Duk; K H Groenier; H W de Bruijn; H Hollema; K A ten Hoor; A G van der Zee; J G Aalders
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

Review 8.  The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review.

Authors:  Ziqi Zhou; Wenbo Li; Fuquan Zhang; Ke Hu
Journal:  PLoS One       Date:  2017-12-11       Impact factor: 3.240

9.  Preoperative nomogram for the identification of lymph node metastasis in early cervical cancer.

Authors:  D-Y Kim; S-H Shim; S-O Kim; S-W Lee; J-Y Park; D-S Suh; J-H Kim; Y-M Kim; Y-T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2013-11-14       Impact factor: 7.640

10.  Tumor grading of soft tissue sarcomas using MRI-based radiomics.

Authors:  Jan C Peeken; Matthew B Spraker; Carolin Knebel; Hendrik Dapper; Daniela Pfeiffer; Michal Devecka; Ahmed Thamer; Mohamed A Shouman; Armin Ott; Rüdiger von Eisenhart-Rothe; Fridtjof Nüsslin; Nina A Mayr; Matthew J Nyflot; Stephanie E Combs
Journal:  EBioMedicine       Date:  2019-09-12       Impact factor: 8.143

View more
  1 in total

1.  A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.

Authors:  Xingxing Zheng; Jingjing Shao; Linli Zhou; Li Wang; Yaqiong Ge; Gaoren Wang; Feng Feng
Journal:  Ther Innov Regul Sci       Date:  2021-10-26       Impact factor: 1.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.